Brind.
  1. Revolution Medicines is advancing trials for various cancers, including metastatic PDAC, NSCLC, and CRC, leveraging RAS inhibitors and targeted therapies, alongside benefits from tariffs and analyst upgrades.

daraxonrasib received Breakthrough Therapy Designation from the FDA for metastatic pancreatic ductal adenocarcinoma.

14 reports, 3 independent Updated Aug 29
Gone quiet
Reports
14
Developments
2
Repetition
86%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

daraxonrasib received Breakthrough Therapy Designation from the FDA for metastatic pancreatic ductal adenocarcinoma.

Who's involved

What this event is mainly about
Revolution Medicines (United States)FDA

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA grants full approval to daraxonrasib from Revolution Medicines.1 source
  2. FDA granted Breakthrough Therapy Designation to daraxonrasib for metastatic PDAC.

Keep exploring

Part of

Revolution Medicines is advancing trials for various cancers, including metastatic PDAC, NSCLC, and CRC, leveraging RAS inhibitors and targeted therapies, alongside benefits from tariffs and analyst upgrades. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
10 more outlets ran the same wire story